Loading
RAS biologist who founded Onyx Pharmaceuticals and led the NCI's national effort to drug RAS.
Frank McCormick is Professor at the UCSF Helen Diller Family Comprehensive Cancer Center and former Scientific Lead of the RAS Initiative at the National Cancer Institute (NIH). A molecular biologist who has worked on RAS signalling for four decades, he founded Onyx Pharmaceuticals, the company behind the origins of sorafenib and carfilzomib, and served as scientific lead of the NCI RAS Initiative at Frederick National Laboratory. His papers include a Clinical Cancer Research review of KRAS as a therapeutic target and a Cancer Cell commentary on covalent KRAS inhibitors entering the clinic. His work on KRAS and RAS inhibitors bears on pancreatic ductal adenocarcinoma, colorectal cancer and non-small-cell lung cancer.
| Title | Journal | Year |
|---|---|---|
| KRAS as a Therapeutic Target | Clinical Cancer Research | 2015 |
| Sticking it to KRAS: Covalent Inhibitors Enter the Clinic | Cancer Cell | 2020 |
This is the paper that made oncolytic viruses look like precision medicine: a named genetic lesion, a virus built to exploit it, a biomarker to select patients. None of that held. It is the field's most useful cautionary tale, because the drug went into large trials on a mechanism that turned out to be wrong, and the selectivity that does exist has never been reducible to one gene.
The reason pancreatic cancer is the proving ground for RAS drugs: nearly every tumour depends on the same mutant protein, so a drug that works against it works for nearly every patient.
Shares UCSF Helen Diller Family Comprehensive Cancer Center, KRAS G12C-mutant pancreatic ductal adenocarcinoma, KRAS & RAS inhibitors, KRAS.
Shares Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes, UCSF Helen Diller Family Comprehensive Cancer Center, KRAS G12C-mutant pancreatic ductal adenocarcinoma, KRAS & RAS inhibitors.
Shares KRAS & RAS inhibitors, KRAS, Pancreatic ductal adenocarcinoma, Colorectal cancer.
Shares Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes, KRAS G12C-mutant pancreatic ductal adenocarcinoma, KRAS & RAS inhibitors, KRAS.
Shares KRAS G12C-mutant pancreatic ductal adenocarcinoma, KRAS & RAS inhibitors, Metastatic pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma.
Shares KRAS G12C-mutant pancreatic ductal adenocarcinoma, KRAS & RAS inhibitors, Pancreatic ductal adenocarcinoma, Colorectal cancer.
Shares KRAS & RAS inhibitors, KRAS, Pancreatic ductal adenocarcinoma, Colorectal cancer.
Shares KRAS G12C-mutant pancreatic ductal adenocarcinoma, KRAS & RAS inhibitors, KRAS, Pancreatic ductal adenocarcinoma.